Vaccibody.com | Uncategorized
1
archive,category,category-uncategorized,category-1,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-16.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.5.5,vc_responsive

Vaccibody AS, a clinical stage immuno-oncology company, announced today that it has entered into a collaboration with Roche to explore a combination of Vaccibody’s VB10.16 and the PD-L1-blocking immune-checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced cervical cancer. Vaccibody expects to start a phase II...

Vaccibody AS today announced positive 6-months interim results from the phase IIa part of the clinical study VB C-01. This study is a first human dose, open-label, multicenter phase I/IIa study of VB10.16 immunotherapy for the treatment of high grade Cervical Intraepithelial Neoplasia (CIN 2/3)...

Vaccibody AS today announced a new clinical collaboration with Nektar Therapeutics to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s CD-122-biased agonist, NKTR-214. VB10.NEO is designed to specifically activate the patient’s immune system to tumour specific antigens, called neoantigens. NKTR-214 is designed to...